Squarepoint
SMMT icon

Squarepoint’s Summit Therapeutics SMMT Stock Holding History

Squarepoint’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-119,300
Closed -$2.46M – 4843
2025
Q3 		$2.46M Sell
119,300
-297,200
-71% -$7.21M ﹤0.01% 1928
2025
Q2 		$8.86M Buy
416,500
+394,900
+1,828% +$9.01M 0.01% 1136
2025
Q1 		$417K Sell
21,600
-64,300
-75% -$1.29M ﹤0.01% 3470
2024
Q4 		$1.53M Buy
+85,900
New +$1.67M ﹤0.01% 2657

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Squarepoint's SMMT Position: Q2 2026 in Review

Squarepoint increased its Summit Therapeutics (SMMT) stake by 159% in Q2 2026, buying an estimated $17.3M and bringing the position to 1,590,736 shares worth $23.2M. The position accounts for 0.03% of the portfolio, ranked #624.

Squarepoint first reported a position in SMMT in Q4 2020 and has held it in 10 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Squarepoint held 1,590,736 shares of Summit Therapeutics worth $23.2M as of Q2 2026.
  • Squarepoint bought 976,859 Summit Therapeutics shares in Q2 2026, an estimated $17.3M.
  • Summit Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #624 holding.
  • Squarepoint first reported a position in Summit Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.